Join us for an insightful discussion with Drs. Natalia Neparidze and Saad Z. Usmani as we explore treatment strategies for relapsed multiple myeloma following BCMA-targeted therapy failure. With CAR T-cell therapy and bispecific antibodies revolutionizing myeloma treatment, clinicians are now faced with new challenges as patients relapse after BCMA-directed therapies. Through the case of a 62-year-old woman who relapsed one year post-BCMA CAR T-cell therapy, we will discuss mechanisms of resistance, treatment sequencing, and the role of novel agents like selinexor-pomalidomide-dexamethasone. This episode will provide hematologists with practical strategies to navigate post-BCMA treatment failure and optimize patient outcomes. Learning Objectives Understand mechanisms of resistance and progression following BCMA-targeted therapy. Explore non-BCMA treatment options, including alternative targets and novel agents. Recognize key factors influencing treatment selection and patient management.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related